Asset profile
Niraparib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Ovarian Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Non-Small Cell Lung Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
72 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 72 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Niraparib: this drug | Approved | Small molecule | PARP1/2 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| Avutometinib | Approved | Small molecule | RAF/MEK, MEK1/2 and RAF (CRAF, BRAF) | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK |
…and 57 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(46 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (11)
November 2026 (3)
Phase 2Penile CarcinomaRecruiting
Est. primary completion 2026-11 · NCT05526989 · CT.gov ↗
What to watch
Phase 3NeoplasmsActive not recruiting
Est. primary completion 2026-11-26 · NCT03981796 · CT.gov ↗
What to watch
Phase 1Metastatic or Locally Advanced Unresectable Solid TumorsActive not recruiting
Est. primary completion 2026-11-30 · NCT04170153 · CT.gov ↗
What to watch
December 2026 (8)
Phase 1/2Glioma, MalignantNot yet recruiting
Est. primary completion 2026-12 · NCT06258018 · CT.gov ↗
What to watch
Phase 2SCLC,Extensive Stage, SLFN11-positiveRecruiting
Est. primary completion 2026-12 · NCT05718323 · CT.gov ↗
What to watch
Phase 2Recurrent Cervix Cancer, Progressive Cervix CancerActive not recruiting
Est. primary completion 2026-12 · NCT04068753 · CT.gov ↗
What to watch
Phase 3Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Recruiting
Est. primary completion 2026-12 · NCT03903835 · CT.gov ↗
What to watch
Phase 2Metastatic Cancer, Central Nervous System CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04992013 · CT.gov ↗
What to watch
Phase 2Ovarian Neoplasms, Breast NeoplasmsRecruiting
Est. primary completion 2026-12-28 · NCT04641247 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05335993 · CT.gov ↗
What to watch
Phase 1Triple Negative Breast Cancer, Residual DiseaseActive not recruiting
Est. primary completion 2026-12-31 · NCT03945721 · CT.gov ↗
What to watch
2027 (19)
January 2027 (1)
Phase 1/2Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-01-03 · NCT03830918 · CT.gov ↗
What to watch
February 2027 (2)
March 2027 (3)
Phase 1/2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-03 · NCT05784012 · CT.gov ↗
What to watch
Phase 2Ovarian, Fallopian Tube and Primary Peritoneal CarcinomaRecruiting
Est. primary completion 2027-03 · NCT06141265 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2027-03-20 · NCT06594679 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-04-30 · NCT04701307 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Prostate CancerActive not recruiting
Est. primary completion 2027-05 · NCT04194554 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2/3Ovarian Carcinosarcoma, Endometrial CarcinosarcomaRecruiting
Est. primary completion 2027-06 · NCT03651206 · CT.gov ↗
What to watch
Phase 3Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05615818 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-06-01 · NCT04812366 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Sarcoma,Soft Tissue, Sarcoma UterusActive not recruiting
Est. primary completion 2027-08 · NCT05515575 · CT.gov ↗
What to watch
September 2027 (2)
November 2027 (1)
Phase 1/2Metastatic Breast Cancer, HER2 Positive Breast CarcinomaActive not recruiting
Est. primary completion 2027-11-01 · NCT03368729 · CT.gov ↗
What to watch
December 2027 (4)
Phase 3Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain TumorActive not recruiting
Est. primary completion 2027-12 · NCT06388733 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05601440 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-12-31 · NCT05990192 · CT.gov ↗
What to watch
Phase 2Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT04592237 · CT.gov ↗
What to watch
2028 (8)
January 2028 (2)
June 2028 (2)
Phase 2Pancreatic Adenocarcinoma MetastaticRecruiting
Est. primary completion 2028-06 · NCT06747845 · CT.gov ↗
What to watch
Phase 2Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8 …Recruiting
Est. primary completion 2028-06-07 · NCT04947254 · CT.gov ↗
What to watch
July 2028 (1)
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
December 2028 (3)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-12 · NCT05009082 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2028-12-25 · NCT06682780 · CT.gov ↗
What to watch
Phase 2Prostate Cancer, Oligometastatic DiseaseActive not recruiting
Est. primary completion 2028-12-31 · NCT06212583 · CT.gov ↗
What to watch
2029 (5)
April 2029 (1)
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2029-06-30 · NCT06953323 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4Ovarian CancerRecruiting
Est. primary completion 2029-07-28 · NCT06412120 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2029-08-01 · NCT05659381 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Brain MetastasesRecruiting
Est. primary completion 2029-12-31 · NCT05700721 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.